CLINDAMYOCIN 300 MG Tablet 10’S
Description
CLINDAMYOCIN 300 MG
Product Specification
| Packaging size | 10 per Strip |
| Brand | spark |
| Manufacturer | Cadila Healthcare (Zydus) |
| Prescription/Non prescription | Prescription |
| Form | CAPSULES |
| Usage | Anti-Infective |
PRODUCT DESCRIPTION
The usual dose is 150-450 mg every six hours, depending on the severity of the Anti- infectives.Elderly patients
Clindamyocin 300 mg requirements in elderly patients should not be influenced by age alone.
Paediatric population
The usual dose is 3-6 mg/kg every six hours depending on the severity of the infection (not to exceed the adult dose).
Clindamyocin 300 mg capsules are not suitable for children who are unable to swallow them whole. The capsules do not provide exact mg/kg doses therefore it may be necessary to use an alternative formulation in some cases.
Renal impairment
No dose adjustment is necessary in patients with mild to moderate impairment of renal function. In patients with severe renal impairment or anuria, plasma concentration should be monitored. Depending on the results, this measure can make a reduction in dosage or an increase in the dose interval of 8 or even 12 hours necessary.
Hepatic impairment
In patients with moderate to severe hepatic impairment, elimination half-life of clindamycin is prolonged. A reduction in dosage is generally not necessary if clindamycin is administered every 8 hours. However, the plasma concentration of clindamycin should be monitored in patients with severe hepatic impairment. Depending on the results, this measure can make a reduction in dosage or an increase in the dose intervals necessary.
Method of administration
Clindamyocin 300 mg capsules are given orally. The product should always be taken with a full glass of water in an upright position. Absorption of Clindamycin capsules is not appreciably modified by the presence of food. Severe hypersensitivity reactions, including severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving clindamycin therapy. If a hypersensitivity or severe skin reaction occurs, clindamycin should be discontinued and appropriate therapy should be initiated (see sections 4.3 and 4.8).
Clindamycin should only be used in the treatment of serious infections. In considering the use of the product, the practitioner should bear in mind the type of infection and the potential hazard of the diarrhoea which may develop, since cases of colitis have been reported during, or even two or three weeks following, the administration of clindamycin.
Cadila Healthcare Ltd (Zydus)
There are no question found.
Rating & Review
There are no reviews yet.